Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2021
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
17 December 2021 - The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund. ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer
16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, ...
Posted by Michael Wonder on 15 Dec 2021
NICE finally accepts use of rare cancer therapy Poteligeo
15 December 2021 - NICE has reversed its earlier decision not to recommend the use of Kyowa Kirin’s Poteligeo (mogamulizumab). ...
Posted by Michael Wonder on 09 Dec 2021
NICE publish final guidance recommending Aspaveli in adults with ultra rare blood disorder
9 December 2021 - The medicine is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a ...
Posted by Michael Wonder on 29 Nov 2021
NICE publishes draft guidance on new medicine for osteoporosis
25 November 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using romosozumab in ...
Posted by Michael Wonder on 20 Nov 2021
NICE recommends Inrebic for rare blood cancer
19 November 2021 - NICE have issued a final appraisal determination recommending the use of Inrebic (fedratinib) on the NHS for ...
Posted by Michael Wonder on 20 Nov 2021
NICE draft guidance recommends new treatment for spinal muscular atrophy as part of a managed access agreement
19 November 2021 - Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit ...
Posted by Michael Wonder on 10 Nov 2021
NICE terminates appraisal of new, first in class radioenhancer hafnium oxide nanoparticle
10 November 2021 - NBTXR3 is used to treat patients with sarcoma. ...
Posted by Michael Wonder on 06 Nov 2021
NICE recommend dapagliflozin for people with chronic kidney disease
5 November 2021 - In draft guidance published today NICE has recommended dapagliflozin as an option for treating certain people ...
Posted by Michael Wonder on 04 Nov 2021
NICE recommends Namuscla for NHS to treat genetic disorder
4 November 2021 - NICE has published draft guidance which recommends a rebranded form of the drug mexiletine (Namuscla), for ...
Posted by Michael Wonder on 03 Nov 2021
NICE releases guidance on medicine for patients with thyroid cancer
3 November 2021 - Selpercatinib is used to treat patients with advanced RET fusion positive thyroid cancer. ...
Posted by Michael Wonder on 26 Oct 2021
NICE draft guidance does not recommend tucatinib for advanced breast cancer
26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in ...
Posted by Michael Wonder on 21 Oct 2021
NICE recommends gene silencing therapy for porphyria patients on NHS
21 October 2021 - NICE have recommended the use of givosiran, a gene silencing therapy, on the NHS in England, as ...
Posted by Michael Wonder on 18 Oct 2021
NICE approves Ofev for PF-ILD
18 October 2021 - NICE has recommended Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing ...
Posted by Michael Wonder on 18 Oct 2021
New asthma drug approved on NHS branded a ‘wonder drug’
18 October 2021 - NICE has issued a Final Appraisal Determination recommending dupilumab as an add-on maintenance treatment for severe ...